/PRNewswire/ -- LISCure Biosciences Inc. ('LISCure') announced on the

/PRNewswire/ -- LISCure Biosciences Inc.（“LISCure”）宣布

2025 Feb

2025年2月

that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing this regulatory approval from KMFDS highlights LISCure's strong research and development capabilities and technological expertise.

其专有的益生菌成分Mobiome®已获得韩国食品药品安全部（KMFDS）的批准，该成分旨在促进头发健康。获得KMFDS的这一监管批准，彰显了LISCure强大的研发能力和技术专长。

This marks the world's first scientifically validated probiotic ingredient for hair health with plans for both domestic and global commercialization..

这标志着世界上首个经过科学验证的护发益生菌成分的诞生，并计划进行国内和全球商业化。

Mobiome®, developed using LISCure's proprietary technology, has demonstrated significant efficacy in preclinical models, enhancing antioxidant activity and exhibiting anti-inflammatory effects.

利用LISCure专有技术开发的Mobiome®在临床前模型中显示出显著的功效，增强了抗氧化活性并表现出抗炎效果。

Mechanistic studies further confirmed its ability to stimulate follicular cell proliferation and regulate follicular cell cycles. In human clinical trials, Mobiome® showed statistically significant improvements in hair glossiness, elasticity, and overall user satisfaction (

机制研究进一步证实了其刺激毛囊细胞增殖和调节毛囊细胞周期的能力。在人体临床试验中，Mobiome® 在头发光泽度、弹性和整体用户满意度方面显示出统计学上的显著改善 (

<0.05, 95% confidence level) across multiple hair-related parameters, including texture, split ends, dryness, breakage, tangling, and damage.

<0.05，95%置信水平）跨越多个与头发相关的参数，包括质地、分叉、干燥、断裂、打结和损伤。

Previously, hair care solutions were limited to pharmaceuticals and topical products such as shampoos. With this regulatory expansion, the hair health market is expected to experience significant growth both domestically and internationally.

此前，头发护理解决方案仅限于药品和洗发水等外用产品。随着这一监管范围的扩大，头发健康市场预计将在国内和国际上实现显著增长。

According to global market research firm Research and Markets, the global hair growth supplement market is projected to grow at a compound annual growth rate (CAGR) of 14.7% from 2023 to 2030, reaching an estimated market value of

根据全球市场研究公司Research and Markets的数据，全球生发补充剂市场预计从2023年到2030年将以14.7%的复合年增长率（CAGR）增长，达到估计的市场价值

$1.92 billion

19.2亿美元

(approximately

（大约

KRW 2.7 trillion

韩元 2.7万亿

) by 2030.

) 到2030年。

LISCure is actively developing functional ingredients targeting hair health, joint health, mental health, weight management, and kidney health, etc.

LISCure正在积极开发针对头发健康、关节健康、心理健康、体重管理和肾脏健康等功能性成分。

In parallel with its functional ingredient business, LISCure is accelerating its global pharmaceutical initiatives. The company has initiated patient dosing for LB-P8, a liver disease treatment that has received IND approval for Phase 2 clinical trials, as well as Orphan Drug designation and Fast Track designation in the U.S.

与功能性成分业务并行，LISCure正在加速其全球制药计划。该公司已开始对LB-P8进行患者给药，这是一种肝病治疗药物，已获得二期临床试验的IND批准，以及美国的孤儿药资格和快速通道资格。

Additionally, LISCure is advancing the joint commercialization of its brain shuttle platform, Exo-Pass N, in collaboration with global pharmaceutical partners. The company is also expediting the development of immuno-oncology therapies targeting colorectal and pancreatic cancers..

此外，LISCure正在与全球制药合作伙伴合作，推进其大脑穿梭平台Exo-Pass N的联合商业化。该公司还在加速开发针对结直肠癌和胰腺癌的免疫肿瘤疗法。

Leveraging the anticipated success of its global drug pipeline and growing revenue from functional ingredients, LISCure is preparing for an initial public offering (IPO). While prioritizing its core pharmaceutical R&D and technology licensing business, the company aims to establish a stable and sustainable revenue model through its functional health ingredient segment..

利用其全球药物管线预期的成功和功能成分收入的增长，LISCure正在准备进行首次公开募股（IPO）。在优先发展其核心制药研发和技术许可业务的同时，该公司旨在通过其功能性健康成分业务建立稳定且可持续的收入模式。

Hwa-Sup Chin,

陈华燮，

CEO of LISCure Biosciences, stated,

LISCure Biosciences首席执行官表示，

'Securing the world's first regulatory approval for a hair health probiotic is a major milestone in our R&D efforts. By leveraging our proprietary platform technologies, we will continue expanding our pipeline beyond pharmaceuticals to include innovative functional health ingredients. Our strategy is to optimize the balance between therapeutics licensing deal with global big pharma and functional ingredient sales to strengthen our global competitiveness.'.

“获得全球首个头发健康益生菌的监管批准是我们研发工作的一个重要里程碑。通过利用我们专有的平台技术，我们将继续扩展产品线，不仅限于制药领域，还包括创新的功能性健康成分。我们的战略是优化治疗产品与全球大型制药公司的授权交易和功能性成分销售之间的平衡，以增强我们的全球竞争力。”